ProKidney Corp [NASDAQ: PROK] jumped around 3.12 points on Tuesday, while shares priced at $3.73 at the close of the session, up 515.00%.
ProKidney Corp stock is now 60.09% up from its year-to-date (YTD) trading value. PROK Stock saw the intraday high of $4.92 and lowest of $1.02 per share. The company’s 52-week high price is 2.59, which means current price is +710.34% above from all time high which was touched on 07/08/25.
Compared to the average trading volume of 1.13M shares, PROK reached a trading volume of 334148752 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about ProKidney Corp [PROK]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PROK shares is $3.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PROK stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for ProKidney Corp shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on June 30, 2025. While these analysts kept the previous recommendation, JP Morgan raised their target price to Neutral. The new note on the price target was released on September 30, 2024, representing the official price target for ProKidney Corp stock. Previously, the target price had yet another raise to $6, while Guggenheim analysts kept a Buy rating on PROK stock.
How has PROK stock performed recently?
ProKidney Corp [PROK] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 529.96. With this latest performance, PROK shares gained by 373.95% in over the last four-week period, additionally plugging by 115.61% over the last 6 months – not to mention a rise of 120.71% in the past year of trading.
ProKidney Corp [PROK]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and ProKidney Corp [PROK] shares currently have an operating margin of -58713.73% and a Gross Margin at -1497.39%. ProKidney Corp’s Net Margin is presently recorded at -22362.09%.
Return on Equity for this stock declined to -17.24%, with Return on Assets sitting at -17.24%.
Earnings analysis for ProKidney Corp [PROK]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PROK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for ProKidney Corp go to -1.29%.
Insider trade positions for ProKidney Corp [PROK]
There are presently around $41.66%, or 59.55% of PROK stock, in the hands of institutional investors. The top three institutional holders of PROK stocks are: MORGAN STANLEY with ownership of 14.45 million shares, which is approximately 19.034%. SUVRETTA CAPITAL MANAGEMENT, LLC, holding 9.34 million shares of the stock with an approximate value of $$22.98 million in PROK stocks shares; and SUVRETTA CAPITAL MANAGEMENT, LLC, currently with $$9.78 million in PROK stock with ownership which is approximately 5.237%.
